{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,3]],"date-time":"2026-06-03T17:47:48Z","timestamp":1780508868074,"version":"3.54.1"},"reference-count":101,"publisher":"Wiley","issue":"9","content-domain":{"domain":["wiley.com","cochranelibrary.com"],"crossmark-restriction":true},"short-container-title":[],"DOI":"10.1002\/14651858.cd015391","type":"journal-article","created":{"date-parts":[[2022,9,14]],"date-time":"2022-09-14T16:43:11Z","timestamp":1663173791000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["Fluvoxamine for the treatment of COVID-19"],"prefix":"10.1002","volume":"2022","author":[{"given":"John LZ","family":"Nyirenda","sequence":"additional","affiliation":[{"name":"Institute for Evidence in Medicine; Medical Center \u2013 University of Freiburg, Faculty of Medicine, University of Freiburg; Freiburg Germany"},{"name":"Public Health Department, Faculty of Applied Sciences; University of Livingstonia; Mzuzu Malawi"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mario","family":"Sofroniou","sequence":"additional","affiliation":[{"name":"Institute of General Practice\/Family Medicine; Faculty of Medicine, Medical Center \u2013 University of Freiburg; Freiburg Germany"},{"name":"NHS South West England; National Health Service; England UK"},{"name":"Fellow, Royal College of General Practitioners; FRCGP; London UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ingrid","family":"Toews","sequence":"additional","affiliation":[{"name":"Institute for Evidence in Medicine; Medical Center \u2013 University of Freiburg, Faculty of Medicine, University of Freiburg; Freiburg Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Agata","family":"Mikolajewska","sequence":"additional","affiliation":[{"name":"Centre for Biological Threats and Special Pathogens (ZBS), Strategy and Incident Response (ZBS7), Clinical Management and Infection Control (ZBS7.1); Robert Koch Institute; Berlin Germany"},{"name":"Department of Infectious Diseases and Respiratory Medicine; Charit\u00e9 \u2013 Universit\u00e4tsmedizin Berlin, corporate member of Freie Universit\u00e4t Berlin and Humboldt-Universit\u00e4t zu Berlin; Berlin Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cornelius","family":"Lehane","sequence":"additional","affiliation":[{"name":"Department of Anesthesiology; University Heart Center Freiburg, Bad Krozingen; Freiburg Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ina","family":"Monsef","sequence":"additional","affiliation":[{"name":"Faculty of Medicine and University Hospital Cologne, University of Cologne; Department I of Internal Medicine, Center for Integrated Oncology Aachen Bonn Cologne Duesseldorf, Cochrane Haematology; Cologne Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aesha","family":"Abu-taha","sequence":"additional","affiliation":[{"name":"Institute of General Practice\/Family Medicine; Faculty of Medicine, Medical Center \u2013 University of Freiburg; Freiburg Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andy","family":"Maun","sequence":"additional","affiliation":[{"name":"Institute of General Practice\/Family Medicine; Faculty of Medicine, Medical Center \u2013 University of Freiburg; Freiburg Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miriam","family":"Stegemann","sequence":"additional","affiliation":[{"name":"Department of Infectious Diseases and Respiratory Medicine; Charit\u00e9 \u2013 Universit\u00e4tsmedizin Berlin, corporate member of Freie Universit\u00e4t Berlin and Humboldt-Universit\u00e4t zu Berlin; Berlin Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christine","family":"Schmucker","sequence":"additional","affiliation":[{"name":"Institute for Evidence in Medicine; Medical Center \u2013 University of Freiburg, Faculty of Medicine, University of Freiburg; Freiburg Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2022,9,14]]},"reference":[{"issue":"22","key":"10.1002\/14651858.CD015391-BIB0001|cit1","doi-asserted-by":"crossref","first-page":"2292","DOI":"10.1001\/jama.2020.22760","article-title":"Fluvoxamine vs placebo and clinical deterioration in outpatients with symptomatic COVID-19: a randomized clinical trial","volume":"324","author":"Lenze","year":"2020","journal-title":"Journal of the American Medical Association"},{"key":"10.1002\/14651858.CD015391-BIB0002|cit2","unstructured":"A double-blind, placebo-controlled clinical trial of fluvoxamine for symptomatic individuals with COVID-19 infection clinicaltrials.gov\/ct2\/show\/NCT04342663"},{"key":"10.1002\/14651858.CD015391-BIB0003|cit3","unstructured":"Repurposed approved and under development therapies for patients with early-onset COVID-19 and mild symptoms www.clinicaltrials.gov\/ct2\/show\/NCT04727424"},{"issue":"1","key":"10.1002\/14651858.CD015391-BIB0004|cit4","doi-asserted-by":"publisher","first-page":"e42","DOI":"10.1016\/S2214-109X(21)00448-4","article-title":"Effect of early treatment with fluvoxamine on risk of emergency care and hospitalisation among patients with COVID-19: the TOGETHER randomised, platform clinical trial","volume":"10","author":"Reis","year":"2021","journal-title":"Lancet Global Health"},{"issue":"2","key":"10.1002\/14651858.CD015391-BIB0005|cit5","first-page":"260","article-title":"Fluvoxamine in the treatment of patients with COVID-19","volume":"12","author":"Assanovich","year":"2021","journal-title":"Psychiatry, Psychotherapy and Clinical Psychology"},{"issue":"4","key":"10.1002\/14651858.CD015391-BIB0006|cit6","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1002\/pu.30705","article-title":"Study suggests fluvoxamine may limit deterioration from COVID-19","volume":"32","year":"2021","journal-title":"Brown University Psychopharmacology Update"},{"key":"10.1002\/14651858.CD015391-BIB0007|cit7","doi-asserted-by":"publisher","first-page":"787261","DOI":"10.3389\/fphar.2021.787261","article-title":"Low-dose fluvoxamine modulates endocytic trafficking of SARS-CoV-2 spike protein: a potential mechanism for anti-COVID-19 protection by antidepressants","volume":"12","author":"Glebov","year":"2021","journal-title":"Frontiers in Pharmacology"},{"key":"10.1002\/14651858.CD015391-BIB0008|cit8","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s00406-021-01326-z","article-title":"Old drug fluvoxamine, new hope for COVID-19","volume":"2","author":"Hashimoto","year":"2021","journal-title":"European archives of psychiatry and clinical neuroscience"},{"issue":"1","key":"10.1002\/14651858.CD015391-BIB0009|cit9","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1055\/a-1551-3756","article-title":"Candidate Psychotropics against SARS - CoV-2: a narrative review","volume":"55","author":"Khosravi","year":"2022","journal-title":"Pharmacopsychiatry"},{"issue":"1","key":"10.1002\/14651858.CD015391-BIB0010|cit10","doi-asserted-by":"crossref","first-page":"95","DOI":"10.3325\/cmj.2021.62.95","article-title":"Could fluvoxamine keep COVID-19 patients out of hospitals and intensive care units?","volume":"62","author":"Marcec","year":"2021","journal-title":"Croatian Medical Journal"},{"issue":"10","key":"10.1002\/14651858.CD015391-BIB0011|cit11","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1358\/dof.2021.46.10.3335978","article-title":"Repurposing approach of fluvoxamine for COVID-19","volume":"46","author":"McCarthy","year":"2021","journal-title":"Drug Future"},{"issue":"1623","key":"10.1002\/14651858.CD015391-BIB0012|cit12","first-page":"69","article-title":"Fluvoxamine for COVID-19?","volume":"63","year":"2021","journal-title":"Medical Letter on Drugs and Therapeutics"},{"issue":"3","key":"10.1002\/14651858.CD015391-BIB0013|cit13","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1177\/10600280211028242","article-title":"Interventions in an ambulatory setting to prevent progression to severe disease in patients with COVID-19: a systematic review","volume":"56","author":"Murchu","year":"2022","journal-title":"Annals of Pharmacotherapy"},{"key":"10.1002\/14651858.CD015391-BIB0014|cit14","unstructured":"Fluvoxamine for adults with mild to moderate COVID-19 clinicaltrials.gov\/ct2\/show\/record\/NCT04711863"},{"issue":"2","key":"10.1002\/14651858.CD015391-BIB0015|cit15","doi-asserted-by":"crossref","first-page":"ofab050","DOI":"10.1093\/ofid\/ofab050","article-title":"Prospective cohort of fluvoxamine for early treatment of coronavirus disease 19","volume":"8","author":"Seftel","year":"2021","journal-title":"Open Forum Infectious Diseases"},{"key":"10.1002\/14651858.CD015391-BIB0016|cit16","doi-asserted-by":"crossref","first-page":"ofab050","DOI":"10.3389\/fphar.2021.652688","article-title":"Fluvoxamine: a review of its mechanism of action and its role in COVID-19","volume":"12","author":"Sukhatme","year":"2021","journal-title":"Frontiers in Pharmacology"},{"key":"10.1002\/14651858.CD015391-BIB0017|cit17","unstructured":"Fluvoxamine for early treatment of Covid-19 (Stop Covid 2) clinicaltrials.gov\/ct2\/show\/NCT04668950"},{"issue":"3","key":"10.1002\/14651858.CD015391-BIB0018|cit18","first-page":"135","article-title":"Effect of fluvoxamine medicine on cytokine level of COVID-19 patients, hospitalized in ICU ward","volume":"38","author":"Safa","year":"2020","journal-title":"Journal of Medical Council of Iran"},{"key":"10.1002\/14651858.CD015391-BIB0019|cit19","unstructured":"COVID-OUT: early outpatient treatment for SARS-CoV-2 infection (COVID-19) clinicaltrials.gov\/ct2\/show\/NCT04510194."},{"key":"10.1002\/14651858.CD015391-BIB0020|cit20","unstructured":"Fluvoxamine administration in moderate SARS-CoV-2 (COVID-19) infected patients clinicaltrials.gov\/ct2\/show\/record\/NCT04718480"},{"key":"10.1002\/14651858.CD015391-BIB0021|cit21","unstructured":"ACTIV-6: COVID-19 study of repurposed medications clinicaltrials.gov\/ct2\/show\/NCT04885530"},{"key":"10.1002\/14651858.CD015391-BIB0022|cit22","unstructured":"Randomized-controlled trial of the effectiveness of COVID-19 early treatment in community clinicaltrials.gov\/ct2\/show\/record\/NCT05087381"},{"key":"10.1002\/14651858.CD015391-BIB0023|cit23","unstructured":"Effect of combined fluvoxamine with favipiravir versus favipiravir monotherapy in prevention of clinical deterioration among mild to moderate COVID-19 patients monitoring by telemedicine in virtual clinic: open-label randomized controlled trial www.thaiclinicaltrials.org\/show\/TCTR20210615002"},{"key":"10.1002\/14651858.CD015391-BIB0024|cit24","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1136\/bmj.m3379","article-title":"A living WHO guideline on drugs for Covid-19","volume":"m3379","author":"Agarwal","year":"2020","journal-title":"BMJ"},{"issue":"6534","key":"10.1002\/14651858.CD015391-BIB0025|cit25","doi-asserted-by":"publisher","first-page":"1103","DOI":"10.1126\/science.abg7404","article-title":"Immunity to SARS-CoV-2 variants of concern","volume":"371","author":"Altmann","year":"2021","journal-title":"Science"},{"issue":"8","key":"10.1002\/14651858.CD015391-BIB0026|cit26","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD014962","article-title":"Remdesivir for the treatment of COVID-19","author":"Ansems","year":"2021","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"19","key":"10.1002\/14651858.CD015391-BIB0027|cit27","doi-asserted-by":"crossref","first-page":"1813","DOI":"10.1056\/NEJMoa2007764","article-title":"Remdesivir for the treatment of Covid-19","volume":"383","author":"Beigel","year":"2020","journal-title":"New England Journal of Medicine"},{"issue":"9","key":"10.1002\/14651858.CD015391-BIB0028|cit28","doi-asserted-by":"crossref","first-page":"e1003346","DOI":"10.1371\/journal.pmed.1003346","article-title":"Occurrence and transmission potential of asymptomatic and presymptomatic SARS-CoV-2infections: a living systematic review and meta-analysis","volume":"17","author":"Buitrago-Garcia","year":"2020","journal-title":"PloS Medicine"},{"key":"10.1002\/14651858.CD015391-BIB0029|cit29","unstructured":"Chen T Wu D Chen H Yan W Yang D Chen G Clinical characteristics of 113 deceased patients with coronavirus disease 2019: retrospective study BMJ 1 12 10.1136\/bmj.m1091"},{"key":"10.1002\/14651858.CD015391-BIB0030|cit30","unstructured":"Core outcome set developers\u2019 response to COVID-19; April 2021 www.comet-initiative.org\/Studies\/Details\/1538"},{"issue":"5","key":"10.1002\/14651858.CD015391-BIB0031|cit31","doi-asserted-by":"publisher","first-page":"177","DOI":"10.15585\/mmwr.mm7105e1","article-title":"SARS-CoV-2 infection and hospitalization among adults aged\u2265 18 Years, by vaccination status, before and during SARS-CoV-2 B. 1.1. 529 (omicron) variant predominance\u2014Los Angeles County, California, November 7, 2021 to January 8, 2022","volume":"71","author":"Danza","year":"2022","journal-title":"Morbidity and Mortality Weekly Report"},{"key":"10.1002\/14651858.CD015391-BIB0032|cit32","unstructured":"Deeks JJ Higgins JP Altman DG Chapter 10: Analysing data and undertaking meta-analyses. In: Higgins JP, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, et al, editor(s). Cochrane Handbook for Systematic Reviews of Interventions version 6.1 (updated September 2020). Cochrane, 2020 Available from training.cochrane.org\/handbook"},{"key":"10.1002\/14651858.CD015391-BIB0033|cit33","unstructured":"Blankenfeld H Kaduszkiewicz H Kochen MM P\u00f6msl J Scherer M SARS-CoV-2\/Covid-19information and practical aids for established general practitioners and general practitioners (Version 22) www.degam-leitlinien.de\/"},{"issue":"7109","key":"10.1002\/14651858.CD015391-BIB0034|cit34","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1136\/bmj.315.7109.629","article-title":"Bias in meta-analysis detected by a simple, graphical test","volume":"315","author":"Egger","year":"1997","journal-title":"BMJ"},{"issue":"4","key":"10.1002\/14651858.CD015391-BIB0035|cit35","first-page":"925","article-title":"Fluvoxamine. An updated review of its use in the management of adults with anxiety disorders","volume":"60","author":"Figgitt","year":"2000","journal-title":"SpringerLink"},{"issue":"18","key":"10.1002\/14651858.CD015391-BIB0036|cit36","doi-asserted-by":"publisher","first-page":"1666","DOI":"10.1056\/nejmp1408480","article-title":"Antidepressants' black-box warning \u2014 10 years later","volume":"371","author":"Friedman R","year":"2014","journal-title":"New England Journal of Medicine"},{"issue":"16","key":"10.1002\/14651858.CD015391-BIB0037|cit37","doi-asserted-by":"publisher","first-page":"pii=2100348","DOI":"10.2807\/1560-7917.ES.2021.26.16.2100348","article-title":"Characteristics of SARS-CoV-2 variants of concern B.1.1.7,B.1.351 or P.1: data from seven EU\/EEA countries, weeks 38\/2020 to 10\/2021","volume":"26","author":"Funk","year":"2021","journal-title":"Europe's Journal on Infectious Disease Surveillance, Epidemiology, Prevention and Control"},{"key":"10.1002\/14651858.CD015391-BIB0038|cit38","unstructured":"GRADEpro GDT McMaster University (developed by Evidence Prime)"},{"issue":"4","key":"10.1002\/14651858.CD015391-BIB0039|cit39","doi-asserted-by":"publisher","first-page":"794","DOI":"10.1016\/j.cell.2020.06.040","article-title":"Making sense of mutation: what D614G means for the COVID-19 pandemic remains unclear","volume":"182","author":"Grubaugh","year":"2020","journal-title":"Cell"},{"issue":"21","key":"10.1002\/14651858.CD015391-BIB0040|cit40","doi-asserted-by":"publisher","first-page":"1941","DOI":"10.1056\/NEJMoa2107934","article-title":"Early treatment for Covid-19 with SARS-CoV-2 neutralizing antibody sotrovimab","volume":"385","author":"Gupta","year":"2021","journal-title":"New England Journal of Medicine"},{"key":"10.1002\/14651858.CD015391-BIB0041|cit41","unstructured":"Higgins JP Li T Deeks JJ Chapter 6: Choosing effect measures and computing estimates of effect. In: Higgins JP, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, Welch VA, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 6.1 (updated September 2020. Cochrane, 2020 Available from www.training.cochrane.org\/handbook"},{"key":"10.1002\/14651858.CD015391-BIB0042|cit42","doi-asserted-by":"crossref","unstructured":"Higgins JP Thomas J Chandler J Cumpston M Li T Page MJ Cochrane Handbook for Systematic Reviews of Interventions Version 6.1 (updated September 2020). Cochrane, 2021 Available from www.training.cochrane.org\/handbook","DOI":"10.1002\/9781119536604"},{"key":"10.1002\/14651858.CD015391-BIB0043|cit43","unstructured":"Higgins JP Savovi\u0107 J Page MJ Elbers RG Sterne JA Chapter 8: Assessing risk of bias in a randomized trial. In: Higgins JP, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, Welch VA, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 6.2 (updated February 2021). Cochrane, 2021 Available from www.training.cochrane.org\/handbook"},{"issue":"3","key":"10.1002\/14651858.CD015391-BIB0044|cit44","doi-asserted-by":"publisher","first-page":"447","DOI":"10.1016\/j.cell.2021.12.032","article-title":"The omicron variant is highly resistant against antibody-mediated neutralization: implications for control of the COVID-19 pandemic","volume":"185","author":"Hoffmann","year":"2021","journal-title":"Cell"},{"issue":"10223","key":"10.1002\/14651858.CD015391-BIB0045|cit45","doi-asserted-by":"publisher","first-page":"497","DOI":"10.1016\/S0140-6736(20)30183-5","article-title":"Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China","volume":"395","author":"Huang","year":"2020","journal-title":"Lancet"},{"issue":"7","key":"10.1002\/14651858.CD015391-BIB0046|cit46","doi-asserted-by":"publisher","first-page":"e010247","DOI":"10.1136\/bmjopen-2015-010247","article-title":"Plea for routinely presenting prediction intervals in meta-analysis","volume":"6","author":"IntHout","year":"2016","journal-title":"BMJ Open"},{"key":"10.1002\/14651858.CD015391-BIB0047|cit47","unstructured":"Jayk Bernal A Gomes da Silva MM Musungaie DB Kovalchuk E Gonzalez A Delos Reyes V et al MOVe-OUT Study Group Molnupiravir for oral treatment of COVID19 in nonhospitalized patients New England Journal of Medicine 2021 1 12 10.1056\/NEJMoa2116044"},{"key":"10.1002\/14651858.CD015391-BIB0048|cit48","unstructured":"Johns Hopkins University & Medicine Coronavirus Resource Center Mortality analyses: How does mortality differ across countries? coronavirus.jhu.edu\/data\/mortality"},{"key":"10.1002\/14651858.CD015391-BIB0049|cit49","unstructured":"Kacimi SE Greca E Haireche MA ElHawary SA Setti MO Caruana R The place of fluvoxamine in the treatment of non-critically ill patients with COVID-19: a living systematic review and meta-analysis medRxiv 2021 10.1101\/2021.12.19.21268044"},{"issue":"10","key":"10.1002\/14651858.CD015391-BIB0050|cit50","doi-asserted-by":"publisher","first-page":"982","DOI":"10.1111\/j.1365-2044.1997.162-az0176.x","article-title":"Selective serotonin reuptake inhibitors Pharmacology and clinical implications in anaesthesia and critical care medicine","volume":"52","author":"Kam","year":"1997","journal-title":"Anaesthesia"},{"issue":"9","key":"10.1002\/14651858.CD015391-BIB0051|cit51","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD013825.pub2","article-title":"SARS-CoV-2-neutralising monoclonal antibodies for treatment of COVID-19","author":"Kreuzberger","year":"2021","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"9","key":"10.1002\/14651858.CD015391-BIB0052|cit52","doi-asserted-by":"publisher","first-page":"577\u201382","DOI":"10.7326\/M20-0504","article-title":"The incubation period of coronavirus disease 2019(COVID-19) from publicly reported confirmed cases: estimation and application","volume":"172","author":"Lauer","year":"2020","journal-title":"Annals of Internal Medicine"},{"key":"10.1002\/14651858.CD015391-BIB0053|cit53","unstructured":"Lee TC Vigod S Bortolussi-Courval E Hanula R Boulware DR Lenze EJ Fluvoxamine for outpatient COVID-19 to prevent hospitalization: a systematic review and meta-analysis medRxiv 10.1101\/2021.12.17.21268008"},{"key":"10.1002\/14651858.CD015391-BIB0054|cit54","unstructured":"Lefebvre C Glanville J Briscoe S Littlewood A Marshall C Metzendorf MI Chapter 4: Searching for and selecting studies. In: Higgins JP, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, Welch VA, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 6.2 (updated February 2021). Cochrane, 2021 Available from www.training.cochrane.org\/handbook"},{"issue":"8","key":"10.1002\/14651858.CD015391-BIB0055|cit55","doi-asserted-by":"crossref","first-page":"e192","DOI":"10.1016\/S1473-3099(20)30483-7","article-title":"A minimal common outcome measure set for COVID-19 clinical research","volume":"20","author":"Marshall","year":"2020","journal-title":"Lancet Infectious Diseases"},{"issue":"10","key":"10.1002\/14651858.CD015391-BIB0056|cit56","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD015045","article-title":"Colchicine for the treatment of COVID-19","author":"Mikolajewska","year":"2021","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"3","key":"10.1002\/14651858.CD015391-BIB0057|cit57","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1177\/10600280211028242","article-title":"Interventions in an ambulatory setting to prevent progression to severe disease in patients with COVID-19: a systematic review","volume":"56","author":"Murchu","year":"2022","journal-title":"Annals of Pharmacotherapy"},{"key":"10.1002\/14651858.CD015391-BIB0058|cit58","unstructured":"National Institutes of Health COVID-19 Treatment Guidelines Panel. Coronavirus Disease 2019 (COVID-19) Treatment Guidelines www.covid19treatmentguidelines.nih.gov\/"},{"key":"10.1002\/14651858.CD015391-BIB0059|cit59","unstructured":"COVID-OUT: early outpatient treatment for SARS-CoV-2 infection (COVID-19) clinicaltrials.gov\/ct2\/show\/NCT04510194"},{"key":"10.1002\/14651858.CD015391-BIB0060|cit60","unstructured":"Fluvoxamine for early treatment of Covid-19 (Stop Covid 2) clinicaltrials.gov\/ct2\/show\/NCT04668950"},{"key":"10.1002\/14651858.CD015391-BIB0061|cit61","unstructured":"Fluvoxamine administration in moderate SARS-CoV-2 (COVID-19) infected patients clinicaltrials.gov\/ct2\/show\/NCT04718480"},{"key":"10.1002\/14651858.CD015391-BIB0062|cit62","unstructured":"ACTIV-6: COVID-19 outpatient randomized trial to evaluate efficacy of repurposed medications clinicaltrials.gov\/ct2\/show\/NCT04885530"},{"key":"10.1002\/14651858.CD015391-BIB0063|cit63","unstructured":"Randomized-controlled trial of the effectiveness of COVID-19 early treatment in community clinicaltrials.gov\/ct2\/show\/record\/NCT05087381"},{"issue":"5","key":"10.1002\/14651858.CD015391-BIB0064|cit64","doi-asserted-by":"publisher","first-page":"362","DOI":"10.7326\/M20-3012","article-title":"Prevalence of asymptomatic SARS-CoV-2infection: a narrative review","volume":"173","author":"Oran","year":"2020","journal-title":"Annals of Internal Medicine"},{"issue":"71","key":"10.1002\/14651858.CD015391-BIB0065|cit65","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1136\/bmj.n71","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","volume":"372","author":"Page","year":"2021","journal-title":"BMJ"},{"issue":"19","key":"10.1002\/14651858.CD015391-BIB0066|cit66","doi-asserted-by":"publisher","first-page":"1915","DOI":"10.1001\/jama.2020.6130","article-title":"Association of public health interventions with the epidemiology of the COVID-19 outbreak in Wuhan, China","volume":"323","author":"Pan","year":"2020","journal-title":"Journal of the American Medical Association"},{"issue":"2","key":"10.1002\/14651858.CD015391-BIB0067|cit67","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD013600.pub4","article-title":"Convalescent plasma or hyperimmune immunoglobulin for people with COVID-19: a living systematic review","author":"Piechotta","year":"2022","journal-title":"Cochrane Database of Systematic Reviews"},{"key":"10.1002\/14651858.CD015391-BIB0068|cit68","doi-asserted-by":"crossref","unstructured":"Planas D Saunders N Maes P Guivel-Benhassine F Planchais C Buchrieser J Considerable escape of SARS-CoV-2 variant Omicron to antibody neutralization Nature 602 7898 671 5 10.1101\/2021.12.14.472630","DOI":"10.1038\/s41586-021-04389-z"},{"issue":"10","key":"10.1002\/14651858.CD015391-BIB0069|cit69","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD015025","article-title":"Antibiotics for the treatment of COVID-19","author":"Popp","year":"2021","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"7","key":"10.1002\/14651858.CD015391-BIB0070|cit70","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD015017.pub2","article-title":"Ivermectin for preventing and treating COVID-19","author":"Popp","year":"2021","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"9","key":"10.1002\/14651858.CD015391-BIB0071|cit71","first-page":"977","article-title":"Fluvoxamine inhibits some inflammatory genes expression in LPS\/stimulated human endothelial cells, U937 macrophages, and carrageenan-induced paw edema in rat","volume":"19","author":"Rafiee","year":"2016","journal-title":"Iranian Journal of Basic Medical Sciences"},{"issue":"12","key":"10.1002\/14651858.CD015391-BIB0072|cit72","doi-asserted-by":"publisher","first-page":"1419","DOI":"10.1016\/S2213-2600(21)00435-5","article-title":"Colchicine in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial","volume":"9","author":"RECOVERY Collaborative Group","year":"2021","journal-title":"Lancet. Respiratory medicine"},{"key":"10.1002\/14651858.CD015391-BIB0073|cit73","unstructured":"Review Manager Web (RevMan Web) The Cochrane Collaboration 2022"},{"issue":"478","key":"10.1002\/14651858.CD015391-BIB0074|cit74","doi-asserted-by":"publisher","first-page":"5266","DOI":"10.1126\/scitranslmed.aau5266","article-title":"Modulation of the sigma-1 receptor\u2013IRE1 pathway is beneficial in preclinical models of inflammation and sepsis","volume":"11","author":"Rosen","year":"2019","journal-title":"Science Translational Medicine"},{"issue":"3","key":"10.1002\/14651858.CD015391-BIB0075|cit75","first-page":"135","article-title":"Effect of fluvoxamine medicine on cytokine level of COVID-19 patients, hospitalized in ICU ward","volume":"30","author":"Safa","year":"2020","journal-title":"Journal of Medical Council of Iran"},{"key":"10.1002\/14651858.CD015391-BIB0076|cit76","doi-asserted-by":"publisher","first-page":"126","DOI":"10.1016\/j.jclinepi.2019.10.014","article-title":"GRADE guidelines 26: informative statements to communicate the findings of systematic reviews of interventions","volume":"119","author":"Santesso","year":"2020","journal-title":"Journal of Clinical Epidemiology"},{"key":"10.1002\/14651858.CD015391-BIB0077|cit77","unstructured":"Sch\u00fcnemann HJ Higgins JP Vist GE Glasziou P Akl EA Skoetz N Chapter 14: Completing 'Summary of findings' tables and grading the certainty of the evidence. In: Higgins JP, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, Welch VA, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 6.1 (updated September 2020). Cochrane, 2020 Available from training.cochrane.org\/handbook"},{"issue":"2","key":"10.1002\/14651858.CD015391-BIB0078|cit78","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD013587.pub2","article-title":"Chloroquine or hydroxychloroquine for prevention and treatment of COVID-19","author":"Singh","year":"2021","journal-title":"Cochrane Database of Systematic Reviews"},{"key":"10.1002\/14651858.CD015391-BIB0079|cit79","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1016\/j.jclinepi.2019.10.015","article-title":"GRADE guidelines 27: how to calculate absolute effects for time-to-event outcomes in summary of findings tables and Evidence Profiles","volume":"118","author":"Skoetz","year":"2020","journal-title":"Journal of Clinical Epidemiology"},{"key":"10.1002\/14651858.CD015391-BIB0080|cit80","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1136\/bmj.l4898","article-title":"RoB 2: a revised tool for assessing risk of bias in randomised trials","volume":"366","author":"Sterne","year":"2019","journal-title":"BMJ"},{"issue":"5","key":"10.1002\/14651858.CD015391-BIB0081|cit81","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD015043","article-title":"Vitamin D supplementation for the treatment of COVID-19: a living systematic review","author":"Stroehlein","year":"2021","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"7","key":"10.1002\/14651858.CD015391-BIB0082|cit82","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD013665","article-title":"Signs and symptoms to determine if a patient presenting in primary care or hospital outpatient settings has COVID-19 disease","author":"Struyf","year":"2020","journal-title":"Cochrane Database of Systematic Reviews"},{"key":"10.1002\/14651858.CD015391-BIB0083|cit83","doi-asserted-by":"publisher","first-page":"652688","DOI":"10.3389\/fphar.2021.652688","article-title":"Fluvoxamine: a review of its mechanism of action and its role in COVID-19","volume":"12","author":"Sukhatme","year":"2021","journal-title":"Frontiers in Pharmacology"},{"key":"10.1002\/14651858.CD015391-BIB0084|cit84","doi-asserted-by":"publisher","first-page":"874375","DOI":"10.3389\/fphar.2022.874375","article-title":"Profiling differential effects of 5 selective serotonin reuptake inhibitors on TLRs-dependent and -independent IL-6 production in immune cells identifies fluoxetine as preferred anti-inflammatory drug candidate","volume":"13","author":"Takenaka","year":"2022","journal-title":"Frontiers in Pharmacology"},{"key":"10.1002\/14651858.CD015391-BIB0085|cit85","unstructured":"Effect of combined fluvoxamine with favipiravir versus favipiravir monotherapy in prevention of clinical deterioration among mild to moderate COVID-19 patients monitoring by telemedicine in virtual clinic: open-label randomized controlled trial trialsearch.who.int\/Trial2.aspx?TrialID=TCTR20210615002"},{"issue":"1","key":"10.1002\/14651858.CD015391-BIB0086|cit86","doi-asserted-by":"publisher","first-page":"1","DOI":"10.2165\/00003088-199500291-00003","article-title":"Overview of the pharmacokinetics of fluvoxamine","volume":"29","author":"Harten","year":"1995","journal-title":"Clinical Pharmacokinetics"},{"issue":"8","key":"10.1002\/14651858.CD015391-BIB0087|cit87","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD014963","article-title":"Systemic corticosteroids for the treatment of COVID-19","author":"Wagner","year":"2021","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"23","key":"10.1002\/14651858.CD015391-BIB0088|cit88","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1056\/NEJMoa2108163","article-title":"REGEN-COV antibody combination and outcomes in outpatients with Covid-19","volume":"385","author":"Weinreich","year":"2021","journal-title":"New England Journal of Medicine"},{"issue":"1","key":"10.1002\/14651858.CD015391-BIB0089|cit89","doi-asserted-by":"publisher","first-page":"516","DOI":"10.1080\/07853890.2022.2034936","article-title":"Efficacy and safety of three new oral antiviral treatment (molnupiravir, fluvoxamine and Paxlovid) for COVID-19: a meta-analysis","volume":"54","author":"Wen","year":"2022","journal-title":"Annals of Medicine"},{"key":"10.1002\/14651858.CD015391-BIB0090|cit90","unstructured":"World Health Organization Cumulative number of reported probable cases of SARS; 2003 www.who.int\/csr\/sars\/country\/2003_07_11\/en"},{"key":"10.1002\/14651858.CD015391-BIB0091|cit91","unstructured":"World Health Organization Middle East respiratory syndrome coronavirus (MERS-CoV): 2019 www.who.int\/emergencies\/mers-cov\/en"},{"key":"10.1002\/14651858.CD015391-BIB0092|cit92","unstructured":"World Health Organization Report of the WHO-China JointMission on coronavirus disease 2019 (COVID-19) www.who.int\/docs\/default-source\/coronaviruse\/who-china-joint-mission-oncovid-19-final-report"},{"key":"10.1002\/14651858.CD015391-BIB0093|cit93","unstructured":"World Health Organization Estimating mortality from COVID-19 - scientific brief www.who.int\/publications\/i\/item\/WHO-2019-nCoV-Sci-Brief-Mortality-2020"},{"key":"10.1002\/14651858.CD015391-BIB0094|cit94","unstructured":"World Health Organization DraR landscape of COVID-19 candidate vaccines www.who.int\/emergencies\/diseases\/novel-coronavirus-2019\/covid-19-vaccines"},{"key":"10.1002\/14651858.CD015391-BIB0095|cit95","unstructured":"World Health Organization COVID-19 Therapeutic Trial Synopsis www.who.int\/publications\/i\/item\/covid-19-therapeutic-trial-synopsis"},{"key":"10.1002\/14651858.CD015391-BIB0096|cit96","unstructured":"World Health Organization WHO Coronavirus Disease (COVID-19) Dashboard covid19.who.int"},{"key":"10.1002\/14651858.CD015391-BIB0097|cit97","unstructured":"World Health Organization SARS-CoV-2 Variants www.who.int\/csr\/don\/31-december-2020-sars-cov2-variants\/en\/"},{"key":"10.1002\/14651858.CD015391-BIB0098|cit98","unstructured":"World Health Organization Tracking SARS-CoV-2 variants www.who.int\/en\/activities\/tracking-SARS-CoV-2-variants\/"},{"key":"10.1002\/14651858.CD015391-BIB0099|cit99","unstructured":"World Health Organization WHO Coronavirus (COVID-19) Dashboard covid19.who.int\/"},{"issue":"7821","key":"10.1002\/14651858.CD015391-BIB0100|cit100","doi-asserted-by":"publisher","first-page":"430","DOI":"10.1038\/s41586-020-2521-4","article-title":"Factors associated with COVID-19-related death using OpenSAFELY","volume":"584","author":"Williamson","year":"2020","journal-title":"Nature"},{"issue":"13","key":"10.1002\/14651858.CD015391-BIB0101|cit101","doi-asserted-by":"publisher","first-page":"1239","DOI":"10.1001\/jama.2020.2648","article-title":"Characteristics of and important lessons from the coronavirus disease 2019 (COVID-19) outbreak in China: summary of a report of 72314 cases from the Chinese Center for Disease Control and Prevention","volume":"323","author":"Wu","year":"2020","journal-title":"JAMA"}],"container-title":["Cochrane Database of Systematic Reviews"],"original-title":[],"language":"en","deposited":{"date-parts":[[2024,9,5]],"date-time":"2024-09-05T09:45:43Z","timestamp":1725529543000},"score":1,"resource":{"primary":{"URL":"http:\/\/doi.wiley.com\/10.1002\/14651858.CD015391"}},"subtitle":[],"editor":[{"name":"Cochrane Haematology Group","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2022,9,14]]},"references-count":101,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2022,9]]}},"URL":"https:\/\/doi.org\/10.1002\/14651858.cd015391","relation":{},"ISSN":["1465-1858"],"issn-type":[{"value":"1465-1858","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,9,14]]}}}